‘Don’t worry, come forward’: Asian nations get 1st shots
Publish- February 25, 2021, 01:56 AM
UNB NEWS - UNB NEWS
Update- February 25, 2021, 02:16 AM
Malaysia's Prime Minister Muhyiddin Yassin receives the first dose of the Pfizer-BioNTech COVID-19 vaccine at a clinic in Putrajaya, Malaysia, Wednesday, Feb. 24, 2021. (Malaysia Health Ministry via AP)
Many nations in the Asia-Pacific region are rolling out the first shots for COVID-19 this week.
Here’s a look at major developments:
South Korea’s top infectious disease experts warned that vaccines will not bring the disease to a quick end and called for continued vigilance in social distancing and mask wearing as the country prepares to give its first shots on Friday.
Jeong Eun-kyeong, director of the Korea Disease Control and Prevention Agency, said Wednesday it would take a “considerably long time” before the mass vaccination campaign brings the virus under control.
The country aims to vaccinate more than 70% of the population by November. But a safe return to a life without masks is highly unlikely this year, considering various factors including the growing spread of virus variants, said Choi Won Suk, an infectious disease professor at the Korea University Ansan Hospital.
“We are concerned that people might drop their guard as vaccination begins, triggering another massive wave of the virus,” Jeong said.
Jeong spoke as South Korea began transporting the first vaccines rolled off a production line in the southern city of Andong, where local pharmaceutical company SK Bioscience is manufacturing the shots developed by AstraZeneca and the University of Oxford.
The country will kick off the vaccination on Friday starting with residents and employees at long-term care facilities.
Separately, some 55,000 doctors, nurses and other health professionals treating COVID-19 patients will begin receiving the shots developed by Pfizer and BioNTech on Saturday.
Two elderly people have been administered with higher-than-prescribed doses of the Pfizer vaccine, Australia’s health minister said Wednesday.
The 88-year-old man and 94-year-old woman were being monitored and the doctor who administered the shots had been stood down from the vaccination program, Health Minister Greg Hunt said.
The error occurred at the Holy Spirit aged care home in the Brisbane suburb of Carseldine on Tuesday, the day after the vaccine rollout in Australia began, Hunt said.
“Both patients are being been monitored and both patients are showing no signs at all of an adverse reaction,” Hunt said. He did not say how much more than the prescribed dose was injected.
Lincoln Hopper, chief executive of St. Vincent’s Care Services that owns the home, said he was “very concerned” for the residents’ welfare. The woman remained at the home while the man had been admitted to a hospital, Hopper said.
“This incident has been very distressing to us, to our residents and to their families and it’s also very concerning,” Hopper said. “It’s caused us to question whether some of the clinicians given the job of administering the vaccine have received the appropriate training.”
Hunt later revealed that the doctor who administered the overdoses had not completed the online training that all health professionals involved in the program must undertake.
Hunt apologized for earlier telling Parliament that the doctor had been trained. He said he had asked the Health Department to take action against the doctor and the company the doctor works for.
Thailand on Wednesday received the first 200,000 doses of China’s Sinovac vaccine.
Another 117,000 doses of AstraZeneca are expected later Wednesday.
Prime Minister Prayuth Chan-ocha attended a ceremony with the Chinese Embassy deputy mission chief to receive the vaccines at Bangkok’s Suvarnabhumi airport.
Thailand has ordered a total of 2 million doses from China.
Later this year, local manufacturer Siam Bioscience will supply 200 million doses of the AstraZeneca vaccine for the region, of which 26 million are allocated for Thailand. Thai officials have said they had secured an additional deal with AstraZeneca for a total of 61 million doses.
Many critics and opposition parties have criticized the government’s procurement plans as too slow and inadequate.
Thailand, whose economy relies on income from tourism, is aiming to inject 10 million doses a month from June, and plans to inoculate at least half the population by the end of the year.
Prime Minister Muhyiddin Yassin received Malaysia’s first COVID-19 vaccine shot on Wednesday at the start of the inoculation campaign.
“I did not feel anything at all. It was all over before I realize, just like a normal injection. Don’t worry, come forward anytime,” he said at a ceremony broadcast live.
Health Director-General Noor Hisham Abdullah was also among the first to be vaccinated.
Malaysia, which has signed deals with several vaccine suppliers including Pfizer and AstroZeneca, aims to vaccinate up to 80% percent of its 32 million people by next year.
More than half a million health care and front-line workers will be given priority in the first phase.
Chinese regulators are looking at two more potential COVID-19 vaccines, one from state-owned company Sinopharm and another from a private company, CanSino.
Both companies said their vaccine candidates were submitted to regulators this week for approval.
China already has approved two vaccines that it has been using in a mass immunization campaign. One of them is also from Sinopharm, but it was developed by its Beijing subsidiary.
Sinopharm said its vaccine candidate is 72.51% effective. Both shots from Sinopharm rely on inactivated viruses, a traditional technology whereby a live virus is killed and then purified. The inactivated virus then triggers an immune response.
CanSino’s vaccine is a one-dose shot that relies on a harmless common cold virus, called an adenovirus, to deliver the spike gene of the virus into the body. The body then makes the spike proteins, and then generates an immune response. The technology is similar to both Astrazeneca’s and Johnson & Johnson’s vaccines, which rely on different adenoviruses.
CanSino said its vaccine candidate is 65.28% effective.